What we won't sell,
on the record.

Insulin's therapeutic window is among the narrowest of any peptide. Even intended research applications carry an outsized risk profile that we don't believe a consumer-facing storefront should normalize. Available through institutional channels with clinical oversight; not from us.

Melanotan compounds have an extensive documented record of unverified street synthesis, contaminated batches, and harms from off-label use. Even with a proper COA from a clean batch, the surrounding ecosystem is too distorted for us to participate in cleanly.

GHRP-2 reliably elevates cortisol and prolactin alongside growth hormone, which introduces confounding variables that make most pathway research harder to interpret cleanly. Ipamorelin is the cleaner GHS-R1a agonist for the same research questions; we stock that instead.

Hexarelin is one of the strongest known GH secretagogues — and that strength comes with rapid GHS-R1a desensitization in the published literature. For most sustained-research questions, the alternatives we stock produce more interpretable longitudinal data.

2,4-Dinitrophenol is sometimes asked for under research-use language. It is not a research peptide; it is a mitochondrial uncoupler with a documented fatal-overdose record. We will never stock it. We mention it here so the answer is on the public record.

AAS compounds fall outside our research-peptide focus and have a distinct regulatory and supply-chain context. We don't stock them and don't plan to. There are category-specialist suppliers; we're not one.